

- [32] J. G. Liang *et al.*, “S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates,” *Nat. Commun.*, vol. 12, no. 1, Dec. 2021, doi: 10.1038/s41467-021-21634-1.
- [33] J. Ma *et al.*, “Cryo-electron Microscopy Structure of S-Trimer, a Subunit Vaccine Candidate for COVID-19,” *J. Virol.*, vol. 95, no. 11, May 2021, doi: 10.1128/jvi.00194-21.
- [34] Y. Tao, S. V. Strelkov, V. V. Mesyanzhinov, and M. G. Rossmann, “Structure of bacteriophage T4 fibrin: A segmented coiled coil and the role of the C-terminal domain,” *Structure*, vol. 5, no. 6, pp. 789–798, 1997, doi: 10.1016/S0969-2126(97)00233-5.
- [35] T. Li *et al.*, “SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates,” *Emerg. Microbes Infect.*, vol. 9, no. 1, pp. 2076–2090, 2020, doi: 10.1080/22221751.2020.1821583.
- [36] Y. He, J. Li, S. Heck, S. Lustigman, and S. Jiang, “Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design,” *J. Virol.*, vol. 80, no. 12, pp. 5757–5767, Jun. 2006, doi: 10.1128/JVI.00083-06.
- [37] M. V. Sinogubova, N. A. Orlova, S. V. Kovnir, L. K. Dayanova, and I. I. Vorobiev, “High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector,” *PLoS One*, vol. 16, no. 2, p. e0242890, Feb. 2021, doi: 10.1371/journal.pone.0242890.
- [38] H. Liu *et al.*, “Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo,” *Sci. Rep.*, vol. 7, no. 1, p. 8953, Dec. 2017, doi: 10.1038/s41598-017-09518-1.
- [39] E. K. Thomas, M. Nakamura, D. Wienke, C. M. Isacke, A. Pozzi, and P. Liang, “Endo180 Binds to the C-terminal Region of Type I Collagen,” *J. Biol. Chem.*, vol. 280, no. 24, pp. 22596–22605, Jun. 2005, doi: 10.1074/jbc.M501155200.
- [40] J. Pallesen *et al.*, “Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen,” *Proc. Natl. Acad. Sci. U. S. A.*, vol. 114, no. 35, pp. E7348–E7357, Aug. 2017, doi: 10.1073/pnas.1707304114.
- [41] D. Wrapp *et al.*, “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,” *Science (80-)*, vol. 367, no. 6483, pp. 1260–1263, Mar. 2020, doi: 10.1126/science.abb2507.
- [42] C.-L. L. Hsieh *et al.*, “Structure-based design of prefusion-stabilized SARS-CoV-2 spikes,” *Science (80-)*, vol. 369, no. 6510, pp. 1501–1505, Sep. 2020, doi: 10.1126/science.abd0826.
- [43] R. J. Edwards *et al.*, “Cold sensitivity of the SARS-CoV-2 spike ectodomain,” *Nat. Struct. Mol. Biol.*, vol. 28, no. 2, pp. 128–131, Feb. 2021, doi: 10.1038/s41594-020-00547-5.
- [44] C. Seephetdee *et al.*, “Mice immunized with the vaccine candidate hexapropyl spike produce neutralizing antibodies against sars-cov-2,” *Vaccines*, vol. 9, no. 5, p. 498, May 2021, doi: 10.3390/vaccines9050498.
- [45] W. H. Chen *et al.*, “Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement,” *vaccine*, vol. 38, no. 47, pp. 7533–7541, Nov. 2020, doi: 10.1016/j.vaccine.2020.09.061.
- [46] L. Du *et al.*, “Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity,” *Virology*, vol. 393, no. 1, pp. 144–150, Oct. 2009, doi: 10.1016/j.virol.2009.07.018.
- [47] L. Du *et al.*, “A 219-mer CHO-Expressing Receptor-Binding Domain of SARS-CoV S Protein Induces Potent Immune Responses and Protective Immunity,” *Viral Immunol.*, vol. 23, no. 2, pp. 211–219, Apr. 2010, doi: 10.1089/vim.2009.0090.
- [48] A. Wieland and R. Ahmed, “Fc Receptors in Antimicrobial Protection,” 2019, pp. 119–150.
- [49] J. C. Martyn *et al.*, “Surface display of IgG Fc on baculovirus vectors enhances binding to antigen-presenting cells and cell lines expressing Fc receptors,” *Arch. Virol.*, vol. 154, no. 7, pp. 1129–1138, Jul. 2009, doi: 10.1007/s00705-009-0423-8.
- [50] S. Loureiro, E. Robinson, H. Chen, P. Phapugrangkul, C. Colaco, and I. M. Jones, “Virus Glycoproteins Tagged with the Human Fc Domain as Second Generation Vaccine Candidates,” in *Innovation in Vaccinology*, Dordrecht: Springer Netherlands, 2012, pp. 45–63.
- [51] S. K. Wong, W. Li, M. J. Moore, H. Choe, and M. Farzan, “A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2,” *J. Biol. Chem.*, vol. 279, no. 5, pp. 3197–3201, Jan. 2004, doi: 10.1074/jbc.C300520200.
- [52] W. Ren *et al.*, “Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates,” *vaccine*, vol. 38, no. 35, pp. 5653–5658, Jul. 2020, doi: 10.1016/j.vaccine.2020.06.066.
- [53] L. Du *et al.*, “A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines,” *PLoS One*, vol. 8, no. 12, p. e81587, Dec. 2013, doi: 10.1371/journal.pone.0081587.
- [54] L. Du *et al.*, “Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model,” *vaccine*, vol. 25, no. 15, pp. 2832–2838, Apr. 2007, doi: 10.1016/j.vaccine.2006.10.031.
- [55] S. H. Hong *et al.*, “Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates,” *Sci. Adv.*, vol. 7, no. 22, p. eabg7156, May 2021, doi: 10.1126/sciadv.abg7156.
- [56] S. Bangaru *et al.*, “Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate,” *Science (80-)*, vol. 370, no. 6520, pp. 1089–1094, Sep. 2020, doi: 10.1126/science.abe1502.
- [57] X. Wen *et al.*, “Inclusion of a universal tetanus toxoid CD4+ T cell epitope P2 significantly enhanced the immunogenicity of recombinant rotavirus ΔVP8* subunit parenteral vaccines,” *Vaccine*, vol. 32, no. 35, pp. 4420–4427, Jul. 2014, doi: 10.1016/j.vaccine.2014.06.060.
- [58] Z. Liu *et al.*, “RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response,” *Signal Transduct. Target. Ther.*, vol. 5, no. 1, p. 282, Dec. 2020, doi: 10.1038/s41392-020-00402-5.
- [59] R. N. Kirchdoerfer *et al.*, “Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis,” *Sci. Rep.*, vol. 8, no. 1, p. 15701, Dec. 2018, doi: 10.1038/s41598-018-34171-7.
- [60] W. H. Chen *et al.*, “Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate,” *J. Pharm. Sci.*, vol. 106, no. 8, pp. 1961–1970, Aug. 2017, doi: 10.1016/j.xphs.2017.04.037.
- [61] W. H. Chen *et al.*, “Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate,” *Hum. Vaccines Immunother.*, vol. 10, no. 3, pp. 648–658, Mar. 2014, doi: 10.4161/hv.27464.
- [62] L. Du *et al.*, “Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines,” *Nat. Commun.*, vol. 7, no. 1, p. 13473, Dec. 2016, doi: 10.1038/ncomms13473.
- [63] Q. He *et al.*, “COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations,” *Front. Immunol.*, vol. 12, p. 669339, 2021, doi: 10.3389/fimmu.2021.669339.
- [64] C. Keech *et al.*, “Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine,” *N. Engl. J. Med.*, vol. 383, no. 24, pp. 2320–2332, Dec. 2020, doi: 10.1056/NEJMoa2026920.
- [65] P. T. Heath *et al.*, “Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine,” *N. Engl. J. Med.*, p. NEJMoa2107659, Jun. 2021, doi: 10.1056/nejmoa2107659.